How Fast Do You Lose Weight on Ozempic? A Week-by-Week Timeline

Key Takeaways

• Most patients see 1 to 4 pounds of weight loss in the first month, mostly water and reduced food intake from appetite suppression.
• By week 12, average loss in clinical trials of semaglutide for weight management is roughly 6 percent of starting body weight.
• By week 26, average loss is approximately 10 percent. By week 68, average loss is approximately 14.9 percent (STEP 1).
• Weight loss on Ozempic for type 2 diabetes (1 mg dose) averages 6 to 9 percent of body weight at 40 weeks, lower than Wegovy's 2.4 mg dose because the indication and dosing are different.
• Speed varies. Faster losers typically have stricter calorie deficits, more protein, and consistent strength training. Slower losers often plateau around month 6 and need provider-directed adjustments.

Direct answer (40-60 words)

Most patients lose 1 to 4 pounds in the first month on Ozempic, 5 to 10 percent of body weight by week 26, and roughly 14.9 percent by week 68 at the 2.4 mg semaglutide dose used in the STEP 1 trial (Wilding et al., NEJM 2021). Ozempic's lower 1 mg diabetes dose produces smaller losses, around 6 percent at 40 weeks.

Table of contents

1. The 30-second answer
2. The week-by-week timeline based on trial data
3. Ozempic for diabetes vs Wegovy for weight loss: dose matters
4. What happens in month 1 (titration phase)
5. What happens in months 2 to 3
6. What happens in months 4 to 6
7. What happens in months 7 to 12
8. The plateau and how to break it
9. Why some patients lose faster than others
10. The maintenance phase: keeping it off
11. FAQ
12. Sources
13. Footer disclaimers

The week-by-week timeline based on trial data

The most rigorous published data on weight loss with semaglutide comes from the STEP trials for Wegovy (semaglutide 2.4 mg) and the SUSTAIN trials for Ozempic (semaglutide 0.5 mg to 1 mg).

Trial percentages are averages. About 32 percent of STEP 1 participants lost 20 percent or more by week 68, while 14 percent lost less than 5 percent. Real-world results follow a similar distribution.

For a 220-pound starting point, the STEP 1 average translates to roughly:

• 3 pounds lost by week 4
• 13 pounds lost by week 12
• 23 pounds lost by week 26
• 33 pounds lost by week 68

For the same patient on the SUSTAIN-7 1 mg Ozempic dose, the trajectory is roughly:

• 2 pounds by week 4
• 8 pounds by week 12
• 13 pounds by week 26
• 15 pounds by week 52

Ozempic for diabetes vs Wegovy for weight loss: dose matters

Both drugs are semaglutide. The active molecule is identical. The difference is dose, label, and titration.

Ozempic is approved for type 2 diabetes. Maximum dose is 2 mg weekly, but most patients on Ozempic for diabetes are on 0.5 mg or 1 mg long-term. Weight loss on these doses is real but smaller than what Wegovy produces.

Wegovy is approved for chronic weight management. Maximum dose is 2.4 mg weekly. The titration goes 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg over 16 weeks. The higher dose drives more appetite suppression and slower gastric emptying, which produces larger losses.

If a patient on Ozempic for diabetes wants weight-loss results similar to Wegovy, the path is either to reach the 2 mg Ozempic dose (which often requires off-label prescribing for weight loss) or switch to Wegovy if insurance allows. Switching mid-treatment requires no washout period because the molecule is the same.

What happens in month 1 (titration phase)

The first month on Ozempic is the 0.25 mg starter dose. The dose is intentionally too low to produce meaningful weight loss because the goal is GI-side-effect tolerance, not weight reduction.

What you'll typically see:

• 1 to 4 pounds of loss, much of which is water and reduced food intake from early appetite changes
• Mild nausea in 30 to 40 percent of new patients (Wilding et al., NEJM 2021)
• Reduced appetite within 3 to 7 days of the first injection
• Less interest in high-fat or sugary foods (the "food noise" reduction many patients report)

The 0.25 mg dose is sometimes called "subtherapeutic" because clinical effect is minimal. Patients who don't lose weight in the first month aren't failing; the dose hasn't started doing its job yet.

Common pitfall: stopping early because the scale isn't moving. Most plans require staying on 0.25 mg for 4 weeks, then escalating to 0.5 mg for another 4 weeks before reaching the 1 mg "effective" dose for diabetes or continuing to 1.7 then 2.4 mg for weight loss.

What happens in months 2 to 3

By month 2 most patients are on 0.5 mg weekly. By month 3 most are on 1 mg weekly (or higher if titrating toward Wegovy 2.4 mg).

What you'll typically see:

• 4 to 12 pounds of total loss by week 12 on Wegovy 1.7 mg titration
• 3 to 8 pounds of total loss by week 12 on Ozempic 0.5 to 1 mg
• Steady appetite suppression that no longer feels novel
• Smaller portions feel filling sooner
• Possible early plateau around week 6 to 8 as the body adjusts

This is the period when the medication has clearly started working but the rate of loss isn't yet at its peak. Most providers reassess at week 12 to confirm dose tolerance and weight trajectory before escalating further.

GI side effects often peak during dose escalations and ease at stable doses. Constipation and reflux become more common than nausea by month 2. (See our Zepbound acid reflux protocol for tirzepatide; the semaglutide pattern is similar.)

What happens in months 4 to 6

This is the rapid-loss phase for most patients on a weight-loss-dose semaglutide.

What you'll typically see:

• 8 to 18 pounds of total loss by week 16 on Wegovy
• 6 to 12 pounds on Ozempic 1 mg
• Visible body composition changes (clothes fit differently, face slimming)
• Energy levels stable for most patients, low for a minority
• Appetite suppression now part of the daily baseline

Patients who follow a structured eating plan and resistance training during this phase preserve more lean mass and report better outcomes at month 12. The "diet inside the medication" matters here. Patients who simply eat less of whatever they were eating before lose weight but lose more lean tissue and tend to plateau sooner.

A 2023 systematic review (Wilding et al., Diabetes Obes Metab 2023) found patients who paired GLP-1 therapy with a structured high-protein diet lost about 1.5 percent more body weight at 6 months than those without dietary structure.

What happens in months 7 to 12

Loss rate slows for most patients during this period, even with the same medication and dose.

Why the slowdown:

• Lower body mass means lower basal metabolic rate
• Adaptive thermogenesis (the body defends a new lower weight)
• Reduced calorie deficit relative to maintenance as weight drops
• Loss of lean mass during rapid-loss months reducing total energy expenditure

What you'll typically see at week 52:

• 25 to 40 pounds total on Wegovy 2.4 mg for a 220-pound starting weight
• 12 to 20 pounds total on Ozempic 1 mg for the same starting weight
• Plateau periods of 2 to 6 weeks at a time
• Stable appetite suppression but smaller marginal loss per week

Patients who continue to see weekly losses through month 12 are the minority. The more common pattern is significant loss through month 6, plateaus and slow loss through month 9, and a final smaller loss through month 12.

The plateau and how to break it

A plateau is defined clinically as no net loss for 4 or more consecutive weeks despite consistent medication adherence and dietary intake.

Common causes:

• The current dose is no longer producing enough appetite suppression. Resolution: escalate dose if not at maximum.
• Caloric intake has crept up because food noise reduced and meal sizes felt small but stacked. Resolution: log food for 14 days.
• Loss of lean mass reduced metabolic rate. Resolution: add or intensify resistance training.
• The body adapted (adaptive thermogenesis). Resolution: protein at 0.7 to 1.0 g per pound goal weight, modest calorie reduction, and recommit.
• Sleep, stress, or alcohol elevated cortisol or appetite. Resolution: address each individually.

If a patient at maximum dose has plateaued for 8+ weeks despite the corrections above, dose adjustments are unlikely to help. The conversation shifts to whether the current weight is the medication's effective ceiling for that individual or whether a switch to a different molecule (tirzepatide via Zepbound) is reasonable.

The SURMOUNT-5 head-to-head trial (Aronne et al., NEJM 2024) showed tirzepatide produced about 47 percent more weight loss than semaglutide at 72 weeks. Patients who plateau on semaglutide and switch to tirzepatide often see a second wave of loss.

Why some patients lose faster than others

The variation in published trial response is wide. About 1 in 7 patients in STEP 1 lost less than 5 percent at 68 weeks; about 1 in 3 lost more than 20 percent.

Predictors of faster loss:

• Lower starting BMI (counterintuitive but consistent across trials; very high BMI is associated with slower percentage loss)
• Female sex (women lose roughly 1 to 2 percent more body weight on average than men in semaglutide trials)
• Younger age
• Type 2 diabetes absent (diabetes is associated with slower weight-loss response on GLP-1s, partly due to insulin's anabolic effect)
• Tighter dietary structure during the medication
• Consistent resistance training
• Better sleep (under 6 hours sleep is associated with attenuated GLP-1 response per Spiegel et al. studies)

Predictors of slower loss:

• Type 2 diabetes
• Long-term insulin therapy
• Antipsychotic medications (clozapine, olanzapine specifically)
• Hypothyroidism that's undertreated
• Polycystic ovary syndrome with high androgens
• Major life stress during the trial period

If a patient has any of the slower-loss predictors, expecting trial-average results is unrealistic. Setting an individual goal with a provider, often 5 to 10 percent of body weight at 6 months, is more useful than benchmarking against trial averages.

The maintenance phase: keeping it off

Most published data shows that stopping semaglutide leads to weight regain over 12 to 18 months. The STEP 4 extension trial (Rubino et al., JAMA 2021) found patients who switched from semaglutide to placebo at week 20 regained about two-thirds of their lost weight by week 68. Patients who continued semaglutide kept the weight off and lost more.

Practical implications:

• Semaglutide is a long-term treatment for chronic obesity, not a 6-month intervention.
• Stopping requires a plan: tapering rather than abrupt cessation, intensified lifestyle structure, possibly switching to a different anti-obesity medication.
• Maintenance dose can sometimes be lower than the loss-phase dose. Some patients maintain on 1.7 mg after losing on 2.4 mg.

For patients on Ozempic for diabetes, the maintenance question is moot because the drug is treating the underlying disease. For patients on Wegovy for weight loss, the question is real and worth discussing with a provider before starting.

FAQ

How much weight will I lose in the first month on Ozempic? Most patients lose 1 to 4 pounds in month 1. The first month is the 0.25 mg titration dose, intentionally too low for full clinical effect. Larger losses come in months 2 through 6 as the dose escalates.

How much weight do you lose on Ozempic in 3 months? Average loss at 12 weeks is 6 percent of starting body weight on Wegovy 2.4 mg per the STEP 1 trial, and 3.6 percent on Ozempic 1 mg per SUSTAIN-7. For a 220-pound starting weight that's roughly 13 pounds on Wegovy or 8 pounds on Ozempic.

How much weight do you lose on Ozempic in 6 months? Average loss at 26 weeks is roughly 10.5 percent of starting body weight on Wegovy and 6.1 percent on Ozempic at 1 mg. For a 220-pound starting weight that's about 23 pounds on Wegovy or 13 pounds on Ozempic.

How much weight do you lose on Ozempic in a year? Average loss at 52 weeks is approximately 14.5 percent on Wegovy and 7 percent on Ozempic 1 mg. The full STEP 1 trial duration was 68 weeks with an average 14.9 percent loss on Wegovy.

Why am I not losing weight on Ozempic? Most common reasons: still in titration (under 8 weeks total), under-dosed for your goal, calorie intake higher than estimated, plateau due to adaptive thermogenesis, untreated medical condition (hypothyroidism, sleep apnea), antipsychotic or insulin therapy interfering, or you're losing fat but not weight on the scale due to fluid shifts.

How long does it take Ozempic to start working? Appetite suppression can begin within 3 to 7 days of the first 0.25 mg dose. Measurable weight loss typically begins by week 2 or 3. Full clinical effect requires reaching the maintenance dose at week 12 to 16.

Does Ozempic work the same for everyone? No. About 14 percent of patients in STEP 1 lost less than 5 percent at 68 weeks. About 32 percent lost 20 percent or more. The variation is real and partly genetic, partly behavioral, partly dose-related.

Can you lose weight too fast on Ozempic? Yes. Loss faster than 2 percent of body weight per week is associated with higher rates of gallstones, electrolyte imbalances, and lean-mass loss. Most providers aim for 1 to 2 pounds per week as a sustainable rate.

What's the average weight loss on Ozempic 1 mg? About 6 to 7 percent of starting body weight at 40 to 52 weeks based on SUSTAIN-7 data. For a 220-pound patient that's roughly 13 to 15 pounds.

What's the average weight loss on the 2.4 mg Wegovy dose? 14.9 percent of starting body weight at 68 weeks per STEP 1. For a 220-pound patient that's roughly 33 pounds.

Will I plateau on Ozempic? Most patients plateau at some point, usually between months 6 and 12. Plateau-breaking strategies include dose escalation if not at maximum, dietary recommitment, increased resistance training, sleep optimization, and provider review of medications that may interfere.

What happens if I stop Ozempic? About two-thirds of lost weight returns within 12 months of stopping per STEP 4. Stopping abruptly is associated with rapid appetite return and weight regain. Tapering and committed lifestyle changes during the taper improve regain prevention.

Can I speed up weight loss on Ozempic? Within reason, yes. Resistance training 3 to 4 times weekly, protein at 0.7 to 1.0 g per pound goal weight, sleep at 7 to 9 hours, and a consistent moderate calorie deficit (300 to 500 below maintenance) tend to produce faster loss than the medication alone.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Pratley R, Aroda V, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN-7). Lancet Diabetes Endocrinol. 2018;6:275-286.
3. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325:1414-1425.
4. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide versus semaglutide once weekly for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2024.
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24:1553-1564.
6. Ozempic (semaglutide) injection prescribing information. Novo Nordisk Inc. 2024.
7. Wegovy (semaglutide) injection prescribing information. Novo Nordisk Inc. 2024.
8. Spiegel K, Tasali E, Penev P, Van Cauter E. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Ann Intern Med. 2004;141:846-850.
9. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nat Med. 2022;28:2083-2091.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Zepbound is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.